Bayer serum HER-2/neu
This article was originally published in The Gray Sheet
Executive Summary
Oncoprotein test used in monitoring treatment of metastatic breast cancer is added to Advia Centaur immunoassay system menu, firm announces June 30. Increased levels of HER-2/neu have been associated with more aggressive forms of cancer and poor response to therapy. Other devices offering Bayer's HER-2/neu assay include Immuno1 and Microtiter ELISA systems...
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.